Kaehler, Katharina C.; Wagner, Tobias; Blame, Christine et al.
Fear of progression in patients with low-risk malignant melanoma.JOURNAL OF CLINICAL ONCOLOGY. Bd. 35. 2017
Salzmann, S.; Zimmer, S.; Peveling-Oberhag, A. et al.
Formulations in Germany-the need in daily practiceJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 84-84
Schmitt, J; Haufe, E; Trautmann, F et al.
Forschungsprojekt „Durch UV-Strahlung induzierte bösartige Hauttumore“ – Berufli-che und außerberufliche Exposition gegenüber UV-Strahlung und HautkrebsDermatologie in Beruf und Umwelt. Bd. 65. H. 1. 2017 S. 13-14
Piradashvili, Keti; Simon, Johanna; Passlick, David et al.
Fully degradable protein nanocarriers by orthogonal photoclick tetrazole-ene chemistry for the encapsulation and releaseNANOSCALE HORIZONS. Bd. 2. H. 5. 2017 S. 297-302
Geppert, C.; Neuwirth, J.; Henning, B. et al.
Fulminant Course of a Merkel Cell Carcinoma with Bone Marrow InfiltrationJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 15. 2017 S. 159-159
Reese, I.; Ballmer-Weber, B.; Beyer, K. et al.
German guideline for the management of adverse reactions to ingested histamineALLERGOLOGIE. Bd. 40. H. 8. 2017 S. 327-336
Reese, Imke; Ballmer-Weber, Barbara; Beyer, Kirsten et al.
German Guideline for the Management of Adverse Reactions to ingested Histamine Guideline of the German Society for Allergology and Clinical Immunology (DSACI), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Association of Allergologists (AeDA), and the Swiss Society for Allergology and Immunology (SSAI)ALLERGO JOURNAL. Bd. 26. H. 2. 2017 S. 51-59
Rose, C.; von Stebut, E.
Granulomatous Diseases of the Skin Always a special ChallengeHAUTARZT. Bd. 68. H. 7. 2017 S. 518-519
Maurer, M.; Staubach, P.; Raap, U. et al.
H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE studyCLINICAL AND EXPERIMENTAL ALLERGY. Bd. 47. H. 5. 2017 S. 684-692
Arance, A.; Dummer, R.; Ascierto, P. A. et al.
Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant MelanomaANNALS OF ONCOLOGY. Bd. 28. 2017